

Dynavax Technologies Corp (DVAX) - Financial and Strategic SWOT Analysis Review

<https://marketpublishers.com/r/D350D6A4AD2EN.html>

Date: July 2021

Pages: 51

Price: US\$ 125.00 (Single User License)

ID: D350D6A4AD2EN

Abstracts

Dynavax Technologies Corp (DVAX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.

Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Dynavax Technologies Corp (Dynavax) is an biopharmaceutical company that develops novel vaccines based on Toll-like receptor(TLR) biology and also focuses on Various infectious and inflammatory diseases. The company marketed product Hecplisav-B is an adult vaccine which is indicated for the prevention of hepatitis B. The company's pipeline focuses on combining the innate immune response with other immunomodulatory agents for the treatment of cancer. Its ongoing studies include DV2-HBV-25 for acute myocardial infarction events; DV2-HBV-26 for immune-mediated, herpes zoster, and anaphylaxis events; DV2-HBV-27 for the pregnancy registry and DV2-HBV-24 for end stage renal disease. Dynavax also has a vaccine candidate, CpG 1018 adjuvant, for pertussis. The company operates through its subsidiaries in Germany and India. Dynavax is headquartered in Emeryville, California, the US.

Dynavax Technologies Corp Key Recent Developments

Jun 30,2021: Clover and Dynavax announce commercial supply agreement of Dynavax's CpG 1018 adjuvant for Clover's COVID-19 vaccine candidate

Jun 29,2021: Dynavax Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

May 06,2021: Dynavax Announces First Quarter 2021 Financial Results

Mar 01,2021: Dynavax to Present at the H.C. Wainwright Virtual 2021 Global Life Sciences Conference

Feb 25,2021: Dynavax announces fourth quarter and full year 2020 financial results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Dynavax Technologies Corp - Key Facts
Dynavax Technologies Corp - Key Employees
Dynavax Technologies Corp - Key Employee Biographies
Dynavax Technologies Corp - Major Products and Services
Dynavax Technologies Corp - History
Dynavax Technologies Corp - Company Statement
Dynavax Technologies Corp - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Dynavax Technologies Corp - Business Description
Business Segment: Other revenue
Performance
Business Segment: Total Product Revenue
Performance
R&D Overview
Dynavax Technologies Corp - Corporate Strategy
Dynavax Technologies Corp - SWOT Analysis
SWOT Analysis - Overview
Dynavax Technologies Corp - Strengths
Dynavax Technologies Corp - Weaknesses
Dynavax Technologies Corp - Opportunities
Dynavax Technologies Corp - Threats
Dynavax Technologies Corp - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios

Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Dynavax Technologies Corp, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Dynavax Technologies Corp, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021

Dynavax Technologies Corp, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Jun 30, 2021: Clover and Dynavax announce commercial supply agreement of Dynavax's CpG 1018 adjuvant for Clover's COVID-19 vaccine candidate

Jun 29, 2021: Dynavax Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

May 06, 2021: Dynavax Announces First Quarter 2021 Financial Results

Mar 01, 2021: Dynavax to Present at the H.C. Wainwright Virtual 2021 Global Life Sciences Conference

Feb 25, 2021: Dynavax announces fourth quarter and full year 2020 financial results

Feb 16, 2021: Dynavax to Present at the Cowen 41st Annual Health Care Conference

Feb 11, 2021: Dynavax to Report Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call on February 25, 2021

Feb 08, 2021: Dong Yu, Ph.D., Joins Dynavax as Senior Vice President of Vaccine Research

Jan 20, 2021: Dynavax appoints Kelly MacDonald as Chief Financial Officer

Jan 19, 2021: Dynavax Technologies announces management changes

SECTION 6 – APPENDIX

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Dynavax Technologies Corp, Key Facts
Dynavax Technologies Corp, Key Employees
Dynavax Technologies Corp, Key Employee Biographies
Dynavax Technologies Corp, Major Products and Services
Dynavax Technologies Corp, History
Dynavax Technologies Corp, Subsidiaries
Dynavax Technologies Corp, Key Competitors
Dynavax Technologies Corp, Ratios based on current share price
Dynavax Technologies Corp, Annual Ratios
Dynavax Technologies Corp, Annual Ratios (Cont...1)
Dynavax Technologies Corp, Interim Ratios
Dynavax Technologies Corp, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Dynavax Technologies Corp, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Dynavax Technologies Corp, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Dynavax Technologies Corp, Performance Chart (2016 - 2020)

Dynavax Technologies Corp, Ratio Charts

Dynavax Technologies Corp, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Dynavax Technologies Corp, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021

I would like to order

Product name: Dynavax Technologies Corp (DVAX) - Financial and Strategic SWOT Analysis Review

Product link: <https://marketpublishers.com/r/D350D6A4AD2EN.html>

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/D350D6A4AD2EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970